Abstract
Rociletinib is a new third generation epidermal growth factor receptor tyrosine kinase inhibitor (TKI) treatment for non-small cell lung cancer. Known side effects include hyperglycemia and QT prolongation. We describe the first case of rociletinib associated macroscopic pseudo-T wave alternans with
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
